Immunome is a biopharmaceutical company utilizing our proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics ...
Investor Information. 02-27-24 ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 · April 2024 Corporate ...
Immunome Announces Pricing of Public Offering of Common Stock. 1 2 3 4 … 9 Next. CONTACT US. investors@immunome.com · partnerships@immunome.com. QUICK LINKS ...
Missing: immu | Show results with:immu
The Investor Relations website contains information about ImmunityBio, Inc.'s business for stockholders, potential investors, and financial analysts.
Welcome to Mendus' Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the ...
Investor Relations. Immunovant, Inc. Chau Cheng, Ph.D., M.B.A.. Investor Relations info@immunovant.com. Transfer Agent. Continental Stock Transfer & Trust ...
Missing: immu | Show results with:immu
Recent News · 04-09-24 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 · 02-27-24 ImmuCell Announces Unaudited Financial Results for the ...
Immunic Therapeutics Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 jessica.breu@imux.com. Rx Communications Paula ...
Missing: immu | Show results with:immu
Events & Presentations ; AUA 2024. May 3 - May 6, 2024. booth #1931. Location. San Antonio, TX ; Investor Live Audio Webcast - ANKTIVA Post Approval. Apr 26, 2024.
Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings. To schedule a meeting, please ...
Missing: immu | Show results with:immu
People also ask
Who is the CEO of immunome?
What is the immunome?